-

CANTALOUPE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cantaloupe, Inc. - CTLP

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Cantaloupe, Inc. (NasdaqGS: CTLP) to 365 Retail Markets, LLC. Under the terms of the proposed transaction, shareholders of Cantaloupe will receive $11.20 in cash for each share of Cantaloupe that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-ctlp/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

CONNECT WITH US: FaceBook || Instagram || YouTube || TikTok || LinkedIn

Contacts

Kahn Swick & Foti, LLC
Lewis S. Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
855-768-1857

Industry:

Kahn Swick & Foti, LLC

NASDAQ:CTLP
Release Versions
English

Contacts

Kahn Swick & Foti, LLC
Lewis S. Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
855-768-1857

Social Media Profiles
KSF on Facebook
KSF on Instagram
KSF on LinkedIn
KSF on TikTok
KSF on YouTube
More News From Kahn Swick & Foti, LLC

VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Verve Therapeutics, Inc. (NasdaqGS: VERV) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Verve will receive $10.50 per share in cash, plus one non-tradeable contingent value right per share entitling the holder to receive up to an additional $3.00...

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sage Therapeutics, Inc. (NasdaqGM: SAGE) to Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN). Under the terms of the proposed transaction, Sage shareholders will receive $8.50 per share in cash, plus one non-tradable contingent value right collectively worth up to $3.50 per share in cash payable upon...

TEMPUS AI SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Tempus AI, Inc. - TEM

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company’s shares between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the...
Back to Newsroom